Michael A. Mussallem - May 17, 2021 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
Chairman & CEO, Director
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
May 17, 2021
Transactions value $
$0
Form type
4
Date filed
5/19/2021, 04:30 PM
Next filing
May 25, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $0 +69.6K +58.73% $0.00 188K May 17, 2021 Direct F1
holding EW Common Stock 372K May 17, 2021 401(k) F2
holding EW Common Stock 3.15M May 17, 2021 By Living Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Performance Rights Options Exercise $0 -69.6K -100% $0.00* 0 May 17, 2021 Common Stock 69.6K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 17, 2018, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 3, 2021, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 17, 2021, and the actual number of shares vested are reflected on this Form 4.
F2 Reflects shares represented on the most recent statement of the Issuer's 401(k) Plan Administrator.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.